Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen

Clinical Transplantation

Volumn 23, Issue 4, 2009, Pages 476-483

  Thomas, Lora D ^a   Milstone, Aaron P ^a   Miller, Geraldine G ^a   Loyd, James E ^a   Dummer, J Stephen ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiolitis obliterans syndrome; Cytomegalovirus; Lung transplantation; Preemptive therapy; Prophylaxis

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SERODIAGNOSIS; THERAPY DELAY;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DELAYED GRAFT FUNCTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANCICLOVIR; HEART-LUNG TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; YOUNG ADULT;

EID: 68349131578     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.00990.x     Document Type: Article

References (33)

1. Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991: 10: 638.
2. Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993: 147: 1017.
3. Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005: 26: 691.
4. Keenan RJ, Lega ME, Dummer JS et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991: 51: 433.
5. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997: 114: 195.
6. Levine SM. A survey of clinical practice of lung transplantation in North America. Chest 2004: 125: 1224.
7. Perreas KG, McNeil K, Charman S, Sharples LD, Wreghitt T, Wallwork J. Extended ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant 2005: 24: 583.
8. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999: 116: 1265.
9. Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005: 5: 1462.
10. Palmer SM, Grinnan DC, Reams BD, Steele MP, Messier RH, Davis RD. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004: 18: 179.
11. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005: 40: 704.
12. Brumble LM, Milstone AP, Loyd JE et al. Prevention of cytomegalovirus infection and disease after lung transplantation: Results using a unique regimen employing delayed ganciclovir. Chest 2002: 121: 407.
13. Van den Berg AP, van der Bij W, van Son WJ et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - a report of 130 consecutive patients. Transplantation 1989: 48: 991.
14. Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994: 150: 146.
15. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004: 4: 1635.
16. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870.
17. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. New Engl J Med 1987: 317: 1049.
18. Weill D, Lock BJ, Wewers DL et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. Am J Transplant 2003: 3: 492.
19. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006: 81: 1415.
20. Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemstrom KB. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 2001: 164: 679.
21. Reichenspurner H, Soni V, Nitschke M et al. Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus. J Heart Lung Transplant 1998: 17: 439.
22. Koskinen PK, Kallio EA, Bruggeman CA, Lemstrom KB. Cytomegalovirus infection enhances experimental obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med 1997: 155: 2078.
23. Cerrina J, Le Roy Ladurie F, Herve PH et al. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipients. Transpl Int 1992: 5(Suppl. 1): S242.
24. Chalermskulrat W, Neuringer IP, Schmitz JL et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003: 123: 1825.
25. Husain AN, Siddiqui MT, Holmes EW et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999: 159: 829.
26. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004: 170: 1120.
27. Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt TT, Wallwork J. Bronchiolitis obliterans syndrome: Incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998: 17: 1255.
28. Luckraz H, Sharples L, McNeil K, Wreghitt T, Wallwork J. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant 2003: 22: 287.
29. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003: 75: 2064.
30. Opelz G, Döhler B, Ruhenstroh A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004: 4: 928.
31. Bhorade SM, Lurain NS, Jordan A et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002: 21: 1274.
32. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002: 185: 20.
33. Bauer CC, Jaksch P, Aberle SW et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007: 45: 324.